What is the significance of subcortical cystic change on neuroimaging and how should it be evaluated and managed?

Subcortical Cystic Changes: Evaluation and Management

Subcortical cystic changes on neuroimaging most commonly represent dilated perivascular spaces (Virchow-Robin spaces), which are benign findings that require no treatment when they follow CSF signal intensity, are located adjacent to subarachnoid spaces, and remain stable over time.

Initial Diagnostic Approach

When you encounter subcortical cystic changes, your primary goal is to distinguish benign entities from pathologic processes that require intervention.

Key Imaging Features to Assess

Obtain both MRI and non-contrast CT to fully characterize the lesions 1. The MRI provides superior soft tissue detail while CT excels at detecting calcifications.

Look for these specific characteristics:

• Signal intensity: Lesions should follow CSF signal on all sequences (hypointense on T1, hyperintense on T2, no enhancement)
• Location: Dilated perivascular spaces preferentially occur in the subcortical white matter of the anterior superior temporal gyrus 2
• Relationship to vessels: Identify an adjacent penetrating vessel entering the lesion
• Proximity to subarachnoid space: Benign perivascular spaces connect to CSF spaces
• Surrounding signal: Variable surrounding T2/FLAIR hyperintensity may be present but should not show mass effect 2

Critical Differential Diagnoses

Neurocysticercosis must be excluded, particularly in patients from endemic areas or with travel history. Viable parenchymal cysticerci appear as vesicular lesions with visible scolex on high-resolution imaging, often with surrounding enhancement and edema 1. If suspected, obtain enzyme-linked immunotransfer blot (EITB) serology as confirmatory testing (avoid crude antigen ELISA due to poor sensitivity/specificity) 1.

Megalencephalic leukoencephalopathy with subcortical cysts (MLC) presents with macrocephaly in infancy, diffuse subcortical white matter involvement, and characteristic frontal/temporal subcortical cysts 3, 4. This is relevant only in pediatric patients with developmental abnormalities.

Management Algorithm

For Benign Dilated Perivascular Spaces:

1. No intervention required if lesions demonstrate:

   • CSF signal characteristics on all sequences
   • No enhancement
   • No mass effect
   • Adjacent to subarachnoid space
   • Stability on follow-up imaging (if available)

2. Follow-up imaging at 6 months only if:

   • Initial diagnosis is uncertain
   • Atypical features present (enhancement, mass effect, non-CSF signal)
   • Patient develops new neurological symptoms

3. Biopsy is NOT indicated when classic imaging features are present 2

For Suspected Neurocysticercosis:

If imaging suggests viable parenchymal cysticerci:

1. Perform fundoscopic examination before initiating any anthelmintic therapy (strong recommendation) 1

2. Assess for elevated intracranial pressure or hydrocephalus - if present, manage this FIRST before antiparasitic treatment 1

3. For 1-2 viable cysts: Albendazole monotherapy 15 mg/kg/day (max 1200 mg/day) divided twice daily for 10-14 days with food 1

4. For >2 viable cysts: Combination therapy with albendazole 15 mg/kg/day PLUS praziquantel 50 mg/kg/day for 10-14 days 1

5. Monitor hepatotoxicity and leukopenia if albendazole treatment exceeds 14 days 1

6. Screen for latent tuberculosis and Strongyloides if prolonged corticosteroids are anticipated 1

Common Pitfalls to Avoid

Do not biopsy lesions with classic perivascular space features - one case in the literature confirmed chronic gliosis surrounding dilated perivascular spaces on pathology, but this invasive procedure is unnecessary when imaging is characteristic 2.

Do not mistake perivascular spaces for cystic neoplasms - the anterior superior temporal lobe location is a newly recognized characteristic site for these benign findings 2.

Do not start antiparasitic therapy in neurocysticercosis patients with untreated hydrocephalus or diffuse cerebral edema - manage elevated intracranial pressure first with corticosteroids or surgical intervention 1.

Do not use crude antigen ELISA for neurocysticercosis diagnosis - only EITB has adequate sensitivity and specificity 1.

When to Consult

Consult infectious disease or neurology specialists when:

• Neurocysticercosis is suspected but imaging is atypical
• Multiple cystic lesions with enhancement are present
• Patient has ventricular or subarachnoid involvement
• Elevated intracranial pressure complicates management

The vast majority of subcortical cystic changes represent benign dilated perivascular spaces requiring only reassurance and no follow-up imaging when classic features are present.